BCRX$7.17
$7.22
Chart
Performance
Key Stats
AI BCRX Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
NeutralBioCryst Pharmaceuticals shows mixed signals. While its core business in rare diseases is thematically sound, recent financial performance and technical indicators suggest a neutral stance. Further analysis of upcoming earnings and product pipeline developments is recommended.
Thematic
BioCryst operates in the biotechnology sector, focusing on rare diseases, which presents a strong thematic growth opportunity driven by unmet medical needs and advancements in genetic therapies.
Fundamental
The company's financials show consistent revenue growth but persistent net losses, impacting profitability. The balance sheet is manageable, but the current valuation appears stretched given the earnings performance.
Technical
The stock has experienced a significant decline over the past year. Current technical indicators suggest bearish momentum, with the price trading below key moving averages and facing resistance.
| Factor | Score |
|---|---|
| Rare Disease Focus | 85 |
| Biotechnology Innovation | 75 |
| Product Portfolio Diversification | 60 |
| Regulatory Landscape | 65 |
| Partnerships and Collaborations | 75 |
| Factor | Score |
|---|---|
| Valuation | 45 |
| Profitability | 30 |
| Growth | 70 |
| Balance Sheet Health | 40 |
| Cash Flow | 40 |
| Factor | Score |
|---|---|
| Trend Analysis | 30 |
| Momentum | 40 |
| Volume Confirmation | 45 |
| Support & Resistance | 55 |
AI Investing Checklist
Powered by LiveAIBullish Points (5)
Positive EPS Surprises
The company has reported positive earnings surprises (reported EPS exceeding estimated EPS) in 3 out of the last 5 quarters, with a significant beat of 65.55% in Q3 2024.
Favorable Price-to-Sales Ratio
The Price-to-Sales (P/S) ratio of 3.5 for 2024 is below the 5-year historical average of 5.4, suggesting potential undervaluation relative to past sales performance.
Bearish Points (7)
Consistent Net Losses
The company has consistently reported net losses over the past four fiscal years (2021-2024), with a significant net loss of -$88.88 million in 2024.
Negative P/E Ratio
The trailing Price-to-Earnings (P/E) ratio is negative (-43.9 for TTM), which is not comparable and indicates a lack of profitability.
Calendar
August 2025
4
Next Earnings Date
H: $0.10
A: $0.02
L: $0.00
H: 150.00M
A: 148.02M
L: 143.07M
Profile
BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and injectable protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in preclinical phase; and BCX10013, an oral Factor D inhibitor for complement-mediated diseases, as well as developing Oral C5 Inhibitor and Oral C2 Inhibitor. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Shionogi & Co., Ltd., Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Seasonals
Price Target
17.33 USD
The 39 analysts offering 1 year price forecasts for BCRX have a max estimate of 30.00 and a min estimate of 11.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
AstraZeneca, through its Alexion rare disease unit, is a leading global player in complement-mediated rare diseases (e.g., Soliris, Ultomiris for PNH, aHUS), directly competing with BCRX's pipeline candidate BCX9930 (Factor D inhibitor).
Weight: 90
Takeda is a dominant player in the hereditary angioedema (HAE) prophylaxis market with Takhzyro (lanadelumab), which is a direct, established competitor to BCRX's commercialized HAE product, Orladeyo.
Weight: 88
Apellis develops and commercializes complement inhibitors (e.g., Syfovre, Empaveli) for various complement-mediated diseases, positioning them as a direct competitor or alternative solution in the same therapeutic space as BCRX's BCX9930 program.
Weight: 85
CSL Behring is a major pharmaceutical company with a significant presence in the hereditary angioedema (HAE) treatment market, offering C1 esterase inhibitor therapies like Berinert and Haegarda.